7-Nitro-3-methyl-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepinon-(2) | 4928-07-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 英文名称: 7-Nitro-3-methyl-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepinon-(2)
• 英文别名: 7-Nitro-3-methyl-5-phenyl-2-oxo-1.2-dihydro-1.4-benzodiazepin；3-methyl-7-nitro-5-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one；1H-1,4-Benzodiazepin-2(3H)-one, 3-methyl-5-phenyl-7-nitro-；3-methyl-7-nitro-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one
• CAS: 4928-07-8
• 化学式: C₁₆H₁₃N₃O₃
• 分子量: 295.298
• InChiKey: PRMIWZTXQDCXCT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  22
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  87.3
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• 5-PHENYL-LH-BENZ0 [E] [1,4] DIAZEPINE COMPOUNDS SUBSTITUTED WITH AN HYDROXAMIC ACID GROUP AS HISTONE DEACETYLASE INHIBITORS
  申请人：Paoletti Francesco

  公开号：US20100331316A1

  公开（公告）日：2010-12-30

  Novel hydroxamate histone deacetylase inhibitors of formula (I) wherein X is C═O or CH 2 used as antineoplastic agent.

  化合物(I)是一种新型的羟酰胺组蛋白去乙酰化酶抑制剂，其中X为C═O或CH2，可作为抗肿瘤药物。
• 1,3-dihydro-1,4-benzodiazepine-2-thiones for the treatment of CNS related diseases
  申请人：Hoffmann-La Roche Inc.

  公开号：US11021448B2

  公开（公告）日：2021-06-01

  The present invention provides compounds that are muscarinic M1 receptor positive allosteric modulators (PAM) and useful in the treatment of diseases, mediated by the muscarinic M1 receptor, such as Alzheimer's disease, cognitive impairment, schizophrenia, pain or sleep disorders, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances.

  本发明提供的化合物是毒蕈碱 M1 受体正性异位调节剂 (PAM)，可用于治疗由毒蕈碱 M1 受体介导的疾病，如阿尔茨海默氏症、认知障碍、精神分裂症、疼痛或睡眠障碍；本发明还提供了这些化合物的制造方法、含有这些化合物的药物组合物及其作为治疗活性物质的用途。
• APPARATUS AND METHOD FOR MULTIPLE SIMULTANEOUS SYNTHESIS
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP0663856A1

  公开（公告）日：1995-07-26
• 5-PHENYL-1H-BENZO[E][1, 4]DIAZEPINE COMPOUNDS SUBSTITUTED WITH AN HYDROXAMIC ACID GROUP AS HISTONE DEACETYLASE INHIBITORS
  申请人：Universita' Degli Studi di Firenze

  公开号：EP2231623B1

  公开（公告）日：2013-05-22
• 1,3-DIHYDRO-1,4-BENZODIAZEPINE-2-THIONES FOR THE TREATMENT OF CNS RELATED DISEASES
  申请人：F. Hoffmann-La Roche AG

  公开号：EP3535253A1

  公开（公告）日：2019-09-11